Company

Zero Point Five Therapeutics, Inc.

Zero Point Five Therapeutics develops single-dose treatments for soil-transmitted helminth diseases.

About

Founded in 2018 and based in Maryland, Zero Point Five Therapeutics develops ZP5-9676, a treatment for diseases caused by whipworms, tapeworms and hookworms. The single-dose therapy targets soil-transmitted helminths, including Necator americanus and roundworm. In April 2025, the company raised USD 4.30 million in Series C funding from returning investor TEDCO and other investors.

4Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in